Lungpacer Medical has commenced subject enrolment in its Phase II STimulation to Activate RespIration (STARI) trial, ...

Credit: Getty Images. The TESICO trial compared IV aviptadil vs placebo and IV remdesivir vs placebo in patients with acute hypoxemic respiratory failure due to COVID-19. Aviptadil did not improve ...

Please provide your email address to receive an email when new articles are posted on . Capturing ROX index during the first 12 hours of high-flow nasal cannula therapy yielded favorable sensitivity ...

Please provide your email address to receive an email when new articles are posted on . At 90 days, patients with acute hypoxemic respiratory failure in the ICU who received oxygen therapy with a ...

A study that examined mortality among immunocompromised patients with acute hypoxemic respiratory failure found that high-flow oxygen therapy did not significantly decrease 28-day mortality compared ...

CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

SAN FRANCISCO -- Starting high-flow oxygen right away for young children with acute hypoxemic respiratory failure didn't help them leave the hospital sooner than standard oxygen therapy, the PARIS-2 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The available ...

Despite being a common occurrence in intensive care units, acute hypoxemic respiratory failure requires quick decision-making by medical staff. Today, various non-invasive respiratory support options ...